1

1 Intraoperative calculus or hemorrhage in transurethral seminal vesiculoscopy as a risk factor for

2 recurrent hemospermia

- 3 Cheng-En Mei^{1, 2}, Ju-Chuan Hu², Jian-Ri Li², Kun-Yuan Chiu², Shian-Shiang Wang², Chuan-Shu Chen²
- 4 *
- ⁵ ¹Division of Traumatology, Department of Emergency Medicine, Taichung Veterans General
- 6 Hospital, Taichung, Taiwan
- 7 ²Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung,
- 8 Taiwan
- 9
- 10 * Corresponding author
- 11 E-mail: r2060d@gmail.com (CSC)

12 Abstract

13	We summarized our experience regarding Transurethral Seminal Vesiculoscopy (TUSV) and
14	analyzed both recurrence status and risk factors for recurrence. From January 2010 to December
15	2020, 48 patients with intractable hemospermia received successful TUSV at Taichung Invalids
16	General Hospital. For the intraoperative findings, the five-year Disease-free Survival rates (DFS)
17	were 74.1% in the no calculus group compared to 37.1% in the calculus group with a significant
18	difference (log-rank p = 0.015), 75.0% in the no hemorrhage or no blood clot group compared to
19	43.2% in the hemorrhage or blood clot group with significant difference (log-rank $p = 0.032$).
20	Univariate analysis showed intraoperative calculus ($p = 0.040$; HR: 2.94, 95% CI: 1.05–8.21) to be
21	significantly associated with recurrence ($p < 0.05$). Patients with intractable hemospermia who
22	were diagnosed with stones or blood clots found during TUSV experienced a higher rate of
23	hemospermia recurrence.

24 Introduction

25	Hemospermia, hematospermia, or haematospermia is defined as blood appearance in the
26	semen. [1] The symptom usually resolves spontaneously in most cases. The mechanisms
27	surrounding the occurrence of hemospermia can be inflammation, infection, lithiasis, cyst
28	formation, obstruction, tumor, vascular related, trauma, iatrogenic related and systemic origin.
29	Recommended imaging studies include Transrectal Ultrasound (TRUS), Computed Tomography
30	(CT), and Magnetic Resonance Imaging (MRI). [2] TRUS is less expensive and less diagnostic than
31	the other tests, but is more commonly used as a diagnostic tool. [3, 4]
32	Through advancements in endoscopy technology, in vivo Transurethral Seminal Vesiculoscopy
33	(TUSV) was first introduced in 2002. [5] Subsequently, TUSV has been used as a diagnostic and
34	treatment procedure for recurrent hemospermia, persistent hemospermia and intractable
35	hemospermia, with symptoms persisting over 3 months regardless of medical treatment. [6-11]
36	TUSV also has a higher diagnostic rate than TRUS. [3]
37	The recurrence rate after TUSV treatment has been mentioned to be in a range from 3.4% to
38	11.76%. [6-11] To the best of our knowledge, there are currently no studies investigating
39	recurrence after TUSV. In this study, we sorted through 48 successful cases and analyzed their
40	recurrence status and risk factors for recurrence.

4

41 Materials and Methods

42 Patients

43	This study enrolled patients who had intractable hemospermia and received successful TUSV
44	treatment during the period from January 2010 to December 2020 in Taichung Veterans General
45	Hospital, Taiwan, Republic of China. The diagnosis of hemospermia relied on photos of semen
46	which patients took after sexual activity. The enrolled patients took serum Prostate-specific
47	Antigen (PSA), coagulation tests and TRUS.
48	For the treatment of hemospermia, an empiric antibiotic ciprofloxacin, 400 mg every 12
49	hours per os (PO), was administered for at least 2 weeks. For patients with intractable
50	hemospermia who were willing to undergo surgery to relieve symptoms, we provided TUSV.
51	The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki
52	and was granted by the ethics committee of Taichung Veterans General Hospital, Taiwan, Republic
53	of China. The institutional review board number was CE22060A.
54	Surgical techniques
55	Each patient received either general anesthesia or spinal anesthesia and was placed in the
56	lithotomy position. A semi-rigid ureteroscope (6/7.5-Fr; Olympus, Tokyo, Japan) was inserted into
57	the urethra and introduced to the verumontanum. The bilateral seminal vesicles were then
58	entered through the ejaculation duct or fenestrated from the utricle. Intraoperative
59	manifestations, such as Calculus, hemorrhage, mucosal lesion, were recorded. Seminal vesicle fluid
60	would then be collected for a culture exam. Calculus removal or a biopsy would be performed

5

- 61 depending on intraoperative manifestations. After the procedure, 10ml normal saline with 80mg
- 62 gentamycin irrigation into the seminal vesicle would then be done. [9]

63 Statistical analysis

- 64 Numeric variables are expressed as medians (interquartile ranges) and subsequently
- 65 compared using the Chi-square test, with significance set at p < 0.05. Continuous variables are
- 66 presented as medians (ranges) and compared using the Mann-Whitney U test, with significance
- also set at *p* < 0.05. Rates of Disease-free Survival (DFS) up to January 2022 were calculated using
- 68 the Kaplan-Meier life table method and compared across groups using the log-rank test.
- 69 Differences with *p* values < 0.05 were regarded as statistically significant. Univariate and
- 70 multivariate analysis utilizing Cox proportional hazard ratios were derived for the outcomes of
- 71 interest. All *p* values < 0.05 were considered significant in univariate analysis and thus included in
- 72 multivariate analyses.

6

73 Result

74	Forty-eight (48) patients diagnosed with intractable hemospermia who underwent successful
75	TUSV were studied. All patients achieved remission. Sixteen (16) patients (33.3%) underwent
76	recurrence up until January 2022. The characteristics between recurrence and non- recurrence are
77	shown in Table 1. In TURS findings, 22 non-recurrent patients (68.8%) experienced overall calculus,
78	while 13 recurrent patients (86.7%) had overall calculus. Eight non-recurrent patients (25%) had
79	Seminal Vesicle (SV) or ejaculation duct calculus, while 2 recurrent patients (13.3%) had SV or
80	ejaculation duct calculus. The median time of follow-up was 39.4 months in the non- recurrent
81	group and 49.8 months in the recurrent group. Complications such as epididymitis occurred in only
82	2 cases in the non-recurrent group. The median follow-up period was 40.1 months (range,
83	0.95–134.5 months).

Total (n=48)	Non-recurrence (n=32)		Recurrence (n=16)		<i>p</i> value
Age	54.5	(48.3-63.8)	53.5	(38.3-58.8)	0.330
Duration (months)	12.0	(4.0-23.3)	13.0	(6.0-24.0)	0.676
Diabetes mellitus	2	(6.3%)	1	(6.3%)	1.000
Hypertension	6	(18.8%)	4	(25.0%)	0.712
Previous urinary tract	2	(C 20()	4	(C, 2N)	1 000
infection	Z	(6.3%)	T	(6.3%)	1.000
Urolithiasis history	5	(15.6%)	1	(6.3%)	0.648
Erectile dysfunction	4	(12.5%)	1	(6.3%)	0.652
Sexually transmitted disease	1	(3.1%)	0	(0.0%)	1.000
Anti-platelet agent	2	(6.3%)	3	(20.0%)	0.309
PSA	1.1	(0.6-1.4)	1.0	(0.7-1.7)	0.803
Digital rectal examination					
Elastic consistency	32	(100%)	16	(100%)	
Hard consistency	0	(0%)	0	(0%)	
TRUS findings					
Overall calcification	22	(68.8%)	13	(86.7%)	0.288
Prostate calculus	19	(59.4%)	13	(86.7%)	0.094
SV or ejaculation duct	o		n	(12 20/)	0.465
calculus	0	(23.0%)	Z	(13.3%)	0.405
Post operative complication					
Epididymitis	2	(6.3%)	0	(0.0%)	0.546
Perineal pain	0	(0.0%)	0	(0.0%)	
Follow-up period (months)	39.4	(1.6-66.1)	49.8	(20.9-96.7)	0.120
Time to remission (weeks)	4.0	(3.0-4.0)	4.0	(4.0-7.75)	0.097

Table 1. Characteristics of patients between recurrence and non-recurrence.

Chi-square test or Mann-Whitney U test, Median (IQR). *p<0.05, **p<0.01

Numeric variables expressed as medians (interquartile ranges)

Seminal vesicle (SV)

8

85 Intraoperative findings

86	Intraoperative findings of TUSV between the recurrence and non-recurrence groups	are
----	--	-----

- 87 shown in Table 2. Overall calculus was found in the utricle or SV in 10 non-recurrent patients
- 88 (31.3%) and 9 recurrent patients (56.3%). Hemorrhage was found in the utricle or SV in 11

89 non-recurrent patients (34.4%) and 10 recurrent patients (62.5%).

Total (n=48)	Non-recurrence (n=32)		Recurrence (n=16)		<i>p</i> value
Intraoperative findings					
Overall calculus	10	(31.3%)	9	(56.3%)	0.175
Utricle	10	(31.3%)	7	(43.8%)	0.594
Left SV	3	(10.0%)	4	(26.7%)	0.199
Right SV	2	(6.9%)	1	(6.3%)	1.000
Hemorrhage or blood clot	11	(34.4%)	10	(62.5%)	0.123
Utricle	2	(6.3%)	0	(0.0%)	0.546
Left SV	6	(20.7%)	7	(46.7%)	0.092
Right SV	4	(14.3%)	5	(31.3%)	0.250

Table 2. Intraoperative findings of TUSV between recurrence and non-recurrence.

Chi-square test. **p*<0.05, ***p*<0.01 Seminal vesicle (SV)

90 Disease free survival

91 Regarding the TRUS findings, five-year Disease-free Survival (DFS) rates were 75.0% in the no

- 92 calculus group compared to 59.0% in the overall calculus group, with the Kaplan–Meier survival
- 93 curves represented in Fig 1 (log-rank *p* = 0.273). The five-year DFS rates were 54.5% in the no SV or
- 94 ejaculation duct calculus group compared to 100.0% in the SV or ejaculation duct calculus group,
- 95 with the Kaplan–Meier survival curves represented in Fig 2 (log-rank p = 0.227). In this study, the
- 96 five-year DFS rates taken from the TRUS findings were insignificantly different.

9

97 Fig 1. Kaplan–Meier curves of the disease-free survival rates by TRUS findings of overall

98 calcification. No calcification compared to overall calcification

99 Fig 2. Kaplan–Meier curves of the disease-free survival rates by TRUS findings of SV or

- 100 ejaculation duct stone. No Seminal vesicle (SV) or ejaculation duct calculus compared to SV or
- 101 ejaculation duct calculus.
- 102 For the intraoperative findings, the five-year DFS rates were 74.1% in the no calculus group
- 103 compared to 37.1% in the calculus group, with the Kaplan–Meier survival curves represented in Fig
- 104 3 (log-rank p = 0.015). The five-year DFS rates were 75.0% in the no hemorrhage or blood clot
- 105 group compared to 43.2% in the hemorrhage or blood clot group, with the Kaplan–Meier survival
- 106 curves represented in Fig 4 (log-rank p = 0.032). The five-year DFS rates were 73.7% in the
- 107 negative intraoperative finding group compared to 47.7% in the positive intraoperative finding
- group, with the Kaplan–Meier survival curves represented in Fig 5 (log-rank *p* =0.093). In this study,
- 109 the five-year DFS rates were significant higher in the intraoperative no calculus group when
- 110 compared to the calculus group, and in the no hemorrhage or blood clot group when compared to
- 111 the hemorrhage or blood clot group. The five-year DFS rate was insignificant but trending upward
- 112 in intraoperative negative findings when compared to positive findings.
- 113 Fig3. Kaplan–Meier curves of the disease-free survival rates by intraoperative findings of
- 114 **calculus.** No calculus compared to overall calculus.
- 115 Fig4. Kaplan–Meier curves of the disease-free survival rates by intraoperative findings of
- 116 **hemorrhage or blood clot.** No hemorrhage or blood clot compared to hemorrhage or blood clot.

10

117 Fig5. Kaplan–Meier curves of the disease-free survival rates by intraoperative findings. Negative

- 118 intraoperative finding compared to positive intraoperative finding.
- 119 Univariate analysis showed intraoperative calculus (*p* = 0.040; HR: 2.94, 95% CI: 1.05–8.21) to
- 120 be significantly associated with recurrence, and intraoperative hemorrhage or blood clot (*p* =
- 121 0.068; HR: 2.63, 95% CI: 0.93–7.43) to be insignificant but trending upward with recurrence.
- 122 Multivariate Cox proportional hazard analysis showed intraoperative calculus (*p* = 0.051; HR: 2.80,
- 123 95% CI: 1.00–7.90) to be insignificant but trending upward with recurrence.

124 **Discussion**

125 Effectiveness of preoperative imaging

126 TRUS has been mentioned in other studies as having a lower diagnostic yield for hemospermia.

- 127 [3] In this study, preoperative TRUS provided a low SV or ejaculatory duct stone detection. TUSV
- 128 provides better diagnostic rates than a TRUS exam alone. This result is consistent with previous
- 129 research findings. In this study, TRUS results showed no significant difference in DFS. TRUS
- 130 findings also failed to provide an association with recurrence prediction. Although TRUS is
- relatively less invasive and carries less cost, the diagnostic significance and benefit of TRUS in
- 132 patients with persistent hemospermia requires additional follow-up studies.

11

133 Recurrence and hypothesis of hemospermia

134	The recurrence rate after TUSV treatment is mentioned as being in the range of 3.4% to
135	11.76%. [6-11] Amongst the 48 patients in this study, 16 had recurrent hemospermia, with the
136	recurrence rate being 33.33%, which was higher than other studies. However, the median
137	follow-up time in our study was 40.1 months, while the follow-up time in other studies was 5-24
138	months. [6-11] Compared with the previous study performed in our hospital, the follow-up time
139	was 12 months, with 4 of 34 patients experiencing recurrence at a rate of 11.76%. [9] Our patients
140	were more regionalized so follow-up at the same hospital was easier. The high recurrence rate
141	may be related to the long follow-up time.
142	In our study, recurrence-free survival from intraoperative detected stones, hemorrhages, or
143	blood clot was significantly lower when compared with the undetected group. The current
144	hypothesis is that the occurrence of hemospermia, calculus, strictures and inflammation is a
145	vicious cycle. [3, 12] According to that hypothesis, TUSV could interrupt the vicious cycle in
146	addition to providing a diagnosis. For patients with negative intraoperative findings, we believe
147	that TUSV can block the vicious cycle of stricture and inflammation, thus resulting in symptom
148	relief with low recurrence rates. Inflammation may be worse in patients experiencing stones,
149	hemorrhage, or blood clots as detected by TUSV. Fortunately, TUSV can still stop the vicious
150	cycle and relieve symptoms. Because the inflammation is more severe, the possibility of
151	hemospermia recurrence will also increase.

152 Success rate

153	The success rate of TUSV treatment, as mentioned in the relevant literature, ranges from
154	90.9% to 96.53%.[8, 9, 11] In this study, 51 patients underwent TUSV, while 6 of them received
155	second TUSV due to recurrent hemospermia. Among the total 57 TUSV treatments, 54 of which
156	were successfully performed. Such a success rate of 94.7% is comparable with the studies
157	reported in the relevant literature. The 3 patients whose TUSV failed all received MRI exams. It
158	turned out that one of them had a seminal vesicle cyst, while the other 2 patients had small
159	prostate cysts. These structural abnormalities may affect the orientation of the ejaculatory ducts
160	or the location of the seminal vesicles, thereby affecting the success rate of TUSV.
161	Safety considerations
162	Perineal pain, retrograde ejaculation, epididymitis, prolonged hematuria, rectal injury and
163	urinary incontinence are known complications of TUSV. [9, 14] Only 2 patients in this study had
164	postoperative complication of epididymitis. After antibiotic treatment, the infection in these 2
165	patients was eventually controlled and resolved. Some studies have raised concerns that
166	disruption of normal structures by TUSV could lead to infertility. [14] In recent studies, endoscopic

167 treatments including both TUSV and Transurethral Ejaculation Duct resection (TURED) have shown

168 positive results in the treatment of infertility. [10, 15-18] Real-time TRUS-guided TUSV has also

169 been reported as being a safe procedure that helps avoid rectal injury. [19] Therefore, this study

170 provides strong evidence for the safety of TUSV.

13

171 Limitations and future prospects

172	The present study is retrospective and with a rather small sample size. Further prospective
173	studies with more patients involved would provide more convincing reference and therefore
174	stronger evidence. Besides the aforementioned limitations, the condition of patients with
175	hemospermia usually improves spontaneously without any aggressive treatment. Furuya et al.
176	reported that the spontaneously resolved rate of hemospermia is as high as 88.9%. [19] It is
177	possible that at the time of analysis, this natural process, i.e. hemospermia being relieved
178	spontaneously, had, to a certain extent, contributed to the excellent remission rate after TUSV as
179	well as complicated the assumed cause-and-effect relationship between TUSV and the remission
180	of hemospermia.

181 Conclusion

182 As analyzed and concluded in this present study, intraoperative findings can help assess the

183 risk of recurrent hemospermia. Specifically speaking, stones or blood clots found during TUSV for

184 patients with intractable hemospermia contribute to a higher rate of recurrent hemospermia.

185 Acknowledgments

186 We would like to thank the editors of PLOS ONE and the reviewers for their thoughtful comments

187 that helped us strengthen this article.

14

188 **References**

- 189 1. Kumar, P., S. Kapoor, and V. Nargund, *Haematospermia a systematic review*. Ann R Coll
- 190 Surg Engl, 2006. 88(4): p. 339-42.
- 191 2. Suh, Y., et al., *Etiologic classification, evaluation, and management of hematospermia*.
- 192 Transl Androl Urol, 2017. 6(5): p. 959-972.
- 193 3. Xing, C., et al., *Prospective trial comparing transrectal ultrasonography and transurethral*
- seminal vesiculoscopy for persistent hematospermia. Int J Urol, 2012. 19(5): p. 437-42.
- 195 4. Han, H., et al., *Magnetic resonance imaging compared to ultrasound as the preferred*
- 196 *method for diagnosing intractable haematospermia*. Andrologia, 2021. 53(6): p. e14054.
- 197 5. Yang, S.C., et al., *Transutricular seminal vesiculoscopy*. J Endourol, 2002. 16(6): p. 343-5.
- 198 6. Han, W.K., et al., *Transutricular seminal vesiculoscopy in hematospermia: technical*
- 199 considerations and outcomes. Urology, 2009. 73(6): p. 1377-82.
- 200 7. Kang, P.M., et al., Transutricular seminal vesiculoscopy in the management of symptomatic
- 201 *midline cyst of the prostate.* World J Urol, 2016. 34(7): p. 985-92.
- 202 8. Chen, R., et al., Transurethral seminal vesiculoscopy for recurrent hemospermia: experience
- 203 *from 419 cases.* Asian J Androl, 2018. 20(5): p. 438-441.
- 9. Hu, J.C. and C.S. Chen, *Transurethral seminal vesiculoscopy acts as a therapeutic*
- 205 investigation for intractable hemospermia: Step-by-step illustrations and single-surgeon

206 *experience.* Int J Urol, 2018. 25(6): p. 589-595.

207 10. Liao, L.G., et al., *Etiology of 305 cases of refractory hematospermia and therapeutic options*

- 208 by emerging endoscopic technology. Sci Rep, 2019. 9(1): p. 5018.
- 209 11. Chen, W.K., et al., *Transurethral seminal vesiculoscopy for intractable hematospermia*:
- 210 *experience from 144 patients.* BMC Urol, 2021. 21(1): p. 48.
- 211 12. Ren, Z.J., et al., *Transurethral resection of ejaculatory duct combined with seminal*
- 212 vesiculoscopy for management of persistent or recurrent hemospermia in men with
- 213 *ejaculatory duct obstruction*. BMC Urol, 2020. 20(1): p. 34.
- 214 13. Furuya, S., N. Masumori, and A. Takayanagi, Natural history of hematospermia in 189
- 215 *Japanese men.* Int J Urol, 2016. 23(11): p. 934-940.
- 216 14. Pang, K., B.Z. Dong, and C.H. Han, *Commentary on "Transurethral seminal vesiculoscopy for*
- 217 *recurrent hemospermia: experience from 419 cases".* Asian J Androl, 2020. 22(2): p.
- 218 227-228.
- 219 15. Dong, Q., et al., [Minimally invasive surgery for ejaculatory duct obstruction in infertile
- 220 *men].* Zhonghua Nan Ke Xue, 2016. 22(4): p. 291-3.
- 16. Tang, S.X., H.L. Zhou, and Y.L. Ding, *[Effectiveness of transurethral seminal vesiculoscopy in*
- 222 the treatment of persistent hematospermia, and oligoasthenozoospermia and azoospermia
- *from ejaculatory duct obstruction].* Zhonghua Yi Xue Za Zhi, 2016. 96(36): p. 2872-2875.
- 17. Lira, F.T.N., et al., *Management of Ejaculatory Duct Obstruction by Seminal Vesiculoscopy:*
- 225 *Case Report and Literature Review.* JBRA Assist Reprod, 2020. 24(3): p. 382-386.
- 226 18. Wang, H.B., et al., [Transurethral seminal vesiculoscopy in treatment of
- 227 oligoasthenozoospermia secondary incomplete ejaculatory duct obstruction: A report of 8

228	<i>cases].</i> Beijing Da Xue Xue Bao Yi Xue Ban, 2020. 52(4): p. 642-645.
-----	--

- 229 19. Wang, X.S., et al., Real-time transrectal ultrasound-guided seminal vesiculoscopy for the
- 230 treatment of patients with persistent hematospermia: A single-center, prospective,
- 231 *observational study.* Asian J Androl, 2020. 22(5): p. 507-512.
- 232

233 Supporting information

- 234 S1 File. Raw data. File containing data of TUSV follow-up, TRUS findings, Intraoperative findings
- and recurrence



Fig 1. Kaplan–Meier curves of the disease-free survival rates by 1



Fig 2. Kaplan–Meier curves of the disease-free survival rates by 1



Fig3. Kaplan–Meier curves of the disease-free survival rates by ir



Fig4. Kaplan–Meier curves of the disease-free survival rates by ir



Fig5. Kaplan–Meier curves of the disease-free survival rates by ir